Edwards Lifesciences Corp (EW) is facing a slew of legal issues from investor class action lawsuits concerning alleged securities fraud, causing its stock to underperform compared to competitors on several occasions. Despite these challenges, many investment firms are buying into Edwards Lifesciences, with State Street Corp and Soros Fund Management LLC amongst those purchasing shares. The firm has outlined growth strategy at their Annual Investor Conference and aims to deliver stronger TMTT sales, as highlighted in their Q3 2024 earnings call. However, the company's strong fundamentals have been overshadowed by stock price losses of 39% over the past three years. Furthermore, Edwards Lifesciences missed earnings expectations and revealed weak guidance, causing their stock to fall. The company has also started global layoffs, triggering uncertainty in the market. Yet, the company retains solid investor faith with 85% institutional ownership and is reportedly facing high expectations for Q3 earnings growth. Amid turmoil, Edwards Lifesciences does explore new revenue streams as it sells its 'Critical Care Product Group' to BD for $4.2 billion.
Edwards Lifesciences Corp EW News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 07 Dec 2024 14:59:14 GMT -
Rating -3
- Innovation 4
- Information 4
- Rumor 0
